BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Metrics to compare | BLRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.7x | −2.6x | −0.4x | |
PEG Ratio | −0.09 | −0.01 | 0.00 | |
Price/Book | 0.6x | 1.8x | 2.6x | |
Price / LTM Sales | 9.6x | 10.6x | 3.2x | |
Upside (Analyst Target) | - | 155.3% | 46.7% | |
Fair Value Upside | Unlock | 9.6% | 7.6% | Unlock |